In a report released yesterday, Derek Archila from Wells Fargo assigned a Buy rating to Monte Rosa Therapeutics (GLUE – Research Report), with a price target of $18.00. The company’s shares closed yesterday at $6.09.
According to TipRanks, Archila is a 4-star analyst with an average return of 8.7% and a 45.06% success rate. Archila covers the Healthcare sector, focusing on stocks such as Exelixis, Ascendis Pharma, and Argenx Se.
Currently, the analyst consensus on Monte Rosa Therapeutics is a Strong Buy with an average price target of $16.00.
See Insiders’ Hot Stocks on TipRanks >>
GLUE market cap is currently $305M and has a P/E ratio of -2.30.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Monte Rosa Therapeutics (GLUE) Company Description:
Monte Rosa Therapeutics Inc is a biopharmaceutical company involved in developing a portfolio of novel small molecule precision medicines that employ the body’s natural mechanisms to degrade therapeutically relevant proteins. It has developed a protein degradation platform, called QuEEN, that enables to rapidly identify protein targets and molecular glue degrader, or MGD, product candidates.
Read More on GLUE:
- Monte Rosa Therapeutics Unveils Corporate Strategy Presentation
- Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
- Monte Rosa Therapeutics initiates IND-enabling studies for MRT-8102
- Monte Rosa Therapeutics Announces Initiation of IND Enabling Studies for MRT-8102, A First-in-Class NEK7 Directed Molecular Glue Degrader and NLRP3/IL-1β Pathway Inhibitor
- Wedbush starts Monte Rosa at Outperform on ‘highly differentiated’ programs
